Novo Nordisk, european medicines agency and Ozempic

Novo Nordisk’s Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction.
Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update
Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk reduction.
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of death by 20%.
Europe allows Novo to include reduction of kidney disease in Ozempic label
The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a statement on Thursday.
Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...
FierceBiotech1h
Evotec, Novo Nordisk's drug discovery accelerator debuts first 3 projects, adds 5 partners
LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...
JD Supra22h
Novo Nordisk Faces an Increasing Number of Lawsuits Alleging Harm Caused By Wegovy
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
BioSpace3d
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...
Novo Nordisk: Just The Right Price (Rating Upgrade)
Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.
GEN21h
Novo Nordisk and Evotec Select First Three LAB eN² Drug Discovery Projects
Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.
FiercePharma6d
Novo Nordisk slashes prices of additional insulin products but not until 2026
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
Novo Nordisk’s Ambitious Share Repurchase Program
Novo Nordisk (NVO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...